Imatinib Mesylate PurCert Secondary Reference Standard (Traceable to EP CRS) [Includes all characterization data]

PurCert

Synonym: 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide methanesulfonate, 4-[(4-Methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide mesylate, CGP 57148, Genfat

Linear Formula: C₂₉H₃₁N₇O·CH₄O₃S

Molecular Weight: 589.72 g/mol

CAS Number: 220127-57-1

Properties

Water Solubility	200 g/l - soluble
Assay Purity	>=98%
M pt.	226 °C
Density	0.858 g/cm3
Form	Solid

Safety Information

Hazard Statement(s)	H361d
Precautionary Statement	P201 - P202 - P280 - P308 + P313 - P405 - P501
GHS Pictogram
Signal word	Warning
HS Code	29335990
Storage Temp.	2-8°C
Storage Class	11 - Combustible Solids
UN Number	NA

Description

Application

Imatinib Mesylate is used to treat Chronic Myeloid Leukemia in adults and children. It is used for certain cases of Acute Lymphoblastic Leukemia. It is prescribed for Gastrointestinal Stromal Tumor that contains specific KIT mutations. It is used to treat some rare blood disorders and bone marrow diseases associated with PDGFR abnormalities

Purpose

The primary purpose of Imatinib Mesylate is to stop or slow the growth of cancer cells by inhibiting abnormal enzymes such as BCR-ABL KIT and PDGFR tyrosine kinases. This helps control the disease and improve patient outcomes.

General Description

Imatinib Mesylate is a medicine that blocks specific abnormal proteins (tyrosine kinases) that cause certain cancer cells to grow and multiply. It was one of the first successful targeted cancer therapies and is commonly sold under the brand name Gleevec.

Documents


SDS
COA
Specification
Bulk quote order form
Sample COA